Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta-Reference-Cited by-同舟云学术

Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta

Published:2021-02-23 Issue:4 Volume:38 Page:291-304
ISSN:0888-0018
Container-title:Pediatric Hematology and Oncology
language:en
Short-container-title:Pediatric Hematology and Oncology

Author:

Jain Richa¹^ORCID,Trehan Amita¹,Menon Prema²,Kapoor Rakesh³,Kakkar Nandita⁴,Radhika Srinivasan⁵,Saxena Akshay Kumar⁶,Mittal Bhagwant Rai⁷,Varma Neelam⁸,Samujh Ram²,Bansal Deepak¹^ORCID

Affiliation:

1. Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India

2. Department of Pediatric Surgery, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India

3. Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh, India

4. Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

5. Department of Cytopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

6. Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India

7. Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

8. Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Publisher

Informa UK Limited

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/08880018.2020.1850955

Reference35 articles.

1. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

2. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

3. Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

4. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy

5. Management of Neuroblastoma: ICMR Consensus Document

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing the Outcome of Pediatric Metastatic Neuroblastoma in a Nontransplant Setting in a Developing Country: Retrospective Study from a Tertiary Cancer Center in India;Indian Journal of Medical and Paediatric Oncology;2024-08-26

2. Stem Cell Therapy for High-Risk Neuroblastoma: Stem Cell Transplantation and Targeting Cancer Stem Cells;Comprehensive Hematology and Stem Cell Research;2024

3. Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand;Clinical and Experimental Pediatrics;2022-09-15

4. Treatment outcomes among high‐risk neuroblastoma patients receiving non‐immunotherapy regimen: Multicenter study on behalf of the Thai Pediatric Oncology Group;Pediatric Blood & Cancer;2022-05-13

5. Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource‐limited countries;Pediatric Blood & Cancer;2022-01-27